The ternary complex model suggests that G-protein-coupled receptors resonate between inactive (R) and active (R*) forms. Physiologically, R sites ordinarily predominate with a few R* sites giving rise to basal activity. Agonists recognize, stabilize and increase the R* population, thus altering intracellular activity. There is evidence to suggest the possibility of a spectrum of conformations between R and R*. Our aim is to study the consequences of putative GR (glucagon receptor)-activating mutations using glucagon and partial agonist des-His 
Introduction
The extended ternary complex model for GPCR (G-proteincoupled receptor) activation suggests that they interchange between inactive (R) and active (R * ) states [1, 2] . Classical antagonists bind indiscriminately to R and R * without physiological activity. Inverse agonists bind preferentially to R, shifting the equilibrium towards R, thus decreasing basal levels of activity. In contrast, agonists recognize, stabilize and promote R * formation. Agonists may occupy a low proportion of receptor sites, yet elicit a maximal cellular response or exhibit low-level activity despite high receptor occupancy. Classically, the former are full agonists and the latter, partial agonists. Since occupancy equates to affinity and signalling to efficacy it seems these are independent variables [3] .
Agonist-independent (or constitutive) activity may be increased by receptor overexpression, causing a proportionate increase in R and R * sites or, alternatively, by mutations that shift the R-R * equilibrium towards R * . There is evidence for ligand acting both as agonist and inverse agonist at a GPCR, Key words: cAMP regulatory element (CRE)-luciferase, glucagon, G-protein-coupled receptor (GPCR), mutagenesis, receptor activation, ternary complex. Abbreviations used: CRE, cAMP-response element; GPCR, G-protein-coupled receptor; GR, glucagon receptor; TM, transmembrane. 1 To whom correspondence should be addressed (email phs7nhs@bmb.leeds.ac.uk).
depending on the level of constitutive activity [4] . The ability to discriminate experimentally between different activation pathways is of potential therapeutic value.
The glucagon receptor (GR)
Glucagon, through GR activation, up-regulates blood sugar levels through stimulatory G-protein-linked cAMP release [5] . The GR is a secretin-like GPCR, which characteristically possess large extracellular N-termini with which their respective protein ligands make extensive contacts. Although the commensurate intracellular signalling events remain ill defined, there is little doubt that the TM (transmembrane) bundle transmits the agonist's signal through a series of conformational changes to the intracellularly associated G-protein [6, 7] .
Predictive modelling of the GR
There is little sequence identity between Family-B secretinlike receptors and Family-A rhodopsin-like receptors. However, there are some conserved features. TM3 has a conserved disulphide bond, TM4 a tryptophan, TM6 a proline and TM7 an asparagine residue. TM3 in Family B also has an EXXY motif that corresponds to the Family A D/ERY motif, with the arginine being provided by the intracellular region of an adjacent TM helix. After sequence alignment of these four helices with bovine rhodopsin, a partial TM bundle was constructed using the crystal structure of rhodopsin as a template [8] . The remaining TM helices were built manually, keeping alignments similar to bovine rhodopsin. On 404 and Glu 406 (TM7) had predicted involvement in receptor activation. These residues were singularly mutated in the cDNA encoding the human GR.
Evaluation of receptor mutants
Receptor cDNAs were expressed in HEK-293 cells (human embryonic kidney 293 cells) stably transformed with a vector containing CRE (cAMP-response element) 5 to DNAencoding luciferase [9] . Adenylate cyclase stimulation increases cAMP levels and this promotes phosphorylation of the CRE-binding protein and ultimately luciferase production. Luciferase catalyses the conversion of luciferin into luminescent adenyl-oxyluciferin. Therefore the levels of luminescence theoretically correlate with intracellular cAMP levels. [
125 I]Glucagon competition analyses were used to determine affinities of glucagon and glucagon-NH 2 (a partial agonist des-His 1 -[Glu 9 ]glucagon amide at the rat GR [10] ) for the transiently expressed GRs.
Evidence in support of a continuum of GR active states
Our results indicate that agonist affinity is a poor marker of mutation-induced constitutive activity. [11] .
When compared with wild-type receptors, the increased activity of glucagon-NH 2 suggests that Thr 353 -Cys and Glu 406 -Ala mutant receptors are more readily capable of adopting the fully activated R * conformations necessary for G-protein activation. This is further evidence for the existence of a spectrum of R * states from partially active R * low to fully active R * high . Agonists may preferentially recognize a range of active receptor conformations. A proportion of these sites may be R * high sites. At the other extreme, sites may approximate states from which the agonist would dissociate, having triggered events culminating in signalling (R * low ). This accommodates the observed increased basal levels of activity exhibited by some mutant receptors. Hence, basal activity and agonist affinity may change independently, in contrast with the two-state theory [12] , providing further evidence that activation occurs through a series of conformational events [13] . The existence of a spectrum of receptor active states has potential consequences for rational drug design, particularly since different receptor sites may exhibit variable activation thresholds.
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